Showing 1,721 - 1,740 results of 104,603 for search '(( 100 d decrease ) OR ( 5 ((((step decrease) OR (mean decrease))) OR (a decrease)) ))', query time: 1.64s Refine Results
  1. 1721
  2. 1722

    Fenretinide decreases levels of PAX3/FOXO1 and its target genes in aRMS cell lines. by David Herrero Martín (286820)

    Published 2013
    “…<p>Rh4 and RMS13 cells were treated for 24 hours (A) and 48 hours (B) with different concentrations of fenretinide (0.5–1–5 µM, as indicated). …”
  3. 1723
  4. 1724
  5. 1725
  6. 1726

    (A) Decreased DNA CpG methylation at the CpG island of the gene locus in Th2 cells by Masakatsu Yamashita (46657)

    Published 2011
    “…MeDIP assay was performed using an anti–5-methyl cytidine antibody (5-meC) and a control antibody (Cont.). …”
  7. 1727
  8. 1728

    Decreased remyelination initiation is observed in Scribble cKO mice following focal demyelination in corpus callosum. by Andrew A. Jarjour (343100)

    Published 2015
    “…In the contralateral (unlesioned) hemisphere (CL), no difference was seen in the proportion of axons in the corpus callosum that were myelinated in Scribble cKO compared to wild-type animals (A–C). Fewer remyelinated axons were observed in corpus callosum in the lesion area in Scribble cKO mice (E) relative to controls (D) as quantified in F; 0.4–0.5 μm: WT = 80.0% ± 9.8%, cKO = 41.3% ± 8.9% myelinated; 0.5–0.6 μm: WT = 79.4% ± 6.3%, cKO = 41.5% ± 9.5% myelinated; 0.6–0.7 μm: WT = 91.6% ± 3.0%, cKO = 44.3% ± 8.7% myelinated; >0.7 μm: WT = 92.7% ± 1.9%, cKO = 47.9% ± 2.5% myelinated. …”
  9. 1729
  10. 1730
  11. 1731
  12. 1732
  13. 1733
  14. 1734
  15. 1735
  16. 1736
  17. 1737
  18. 1738
  19. 1739
  20. 1740

    Decreased Serum Level of miR-146a as Sign of Chronic Inflammation in Type 2 Diabetic Patients by Lucy Baldeón R. (674016)

    Published 2014
    “…</p><p></p><p></p><p>Conclusions</p><p>This study shows decreased serum anti-inflammatory miR-146a, increased pro-inflammatory IL-8 and increased HGF (a vascular/insular repair factor) as discriminating markers of failure of glucose control occurring on the background of obesity and dyslipidemia.…”